



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/472130/2016

European Medicines Agency decision

P/0201/2016

of 28 July 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for eculizumab (Soliris), (EMEA-000876-PIP06-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0201/2016

of 28 July 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for eculizumab (Soliris), (EMA-000876-PIP06-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Alexion Europe SAS on 23 November 2015 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 24 June 2016, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation and of its own motion in accordance with Article 12 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for eculizumab (Soliris), concentrate for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for eculizumab (Soliris), concentrate for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for eculizumab (Soliris), concentrate for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This agreed paediatric investigation plan covers all conditions, indications, pharmaceutical forms, routes of administration, measures, timelines, waivers and deferrals, as agreed in the decision P/224/2010 issued on 29 October 2010 and in the decision P/0046/2016 issued on 26 February 2016, including subsequent modifications thereof.

Article 5

This decision is addressed to Alexion Europe SAS, 1-15 avenue Edouard Belin, 92500 - Rueil-Malmaison, France.

Done at London, 28 July 2016

For the European Medicines Agency
Zaide Frias
Head of Division
Human Medicines Research and Development Support
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/854053/2015

London, 24 June 2016

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-000876-PIP06-15

Scope of the application

Active substance(s):

Eculizumab

Invented name:

Soliris

Condition(s):

Prevention of graft rejection following solid organ transplantation

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Alexion Europe SAS

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Alexion Europe SAS submitted for agreement to the European Medicines Agency on 23 November 2015 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 4 January 2016.

Supplementary information was provided by the applicant on 4 April 2016. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Prevention of graft rejection following solid organ transplantation

The waiver applies to:

- the paediatric population from birth to less than 1 year of age;
- concentrate for solution for infusion, intravenous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition

Prevention of graft rejection following solid organ transplantation

2.1.1. Indication(s) targeted by the PIP

Prevention of acute antibody-mediated rejection (AMR) after kidney transplantation

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Concentrate for solution for infusion

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	0	Not applicable.
Clinical studies	1	Study 1 Open-label, single-arm, multicentre trial to evaluate pharmacokinetics, safety and activity of eculizumab in sensitised recipients of a kidney transplant from 1 year to less than 18 years of age
Extrapolation, modelling and simulation studies	2	Study 2 Modelling and simulation study to support dosing of eculizumab in sensitised paediatric recipients after kidney transplantation in study ECU-AMR-303 (Study 1)

		Study 3 Extrapolation study to evaluate the use of eculizumab in the proposed paediatric indication in children from 1 to less than 18 years of age after kidney transplantation
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By April 2022
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of paroxysmal nocturnal haemoglobinuria (PNH)

Authorised indication(s):

- Soliris is indicated in adults and children for the treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH).

2. Treatment of atypical haemolytic uremic syndrome (aHUS)

Authorised indication(s):

- Soliris is indicated in adults and children for the treatment of patients with atypical haemolytic uremic syndrome (aHUS).

Authorised pharmaceutical form(s):

Concentrate for solution for infusion

Authorised route(s) of administration:

Intravenous use